Newly listed or thinly covered: fundamentals appear here once there is enough reported history. Prices and market cap are up to date.
Share price
₹379.65 latest close · −1.6% over the last 90 sessions
₹379.65 month-end · −6.9% over 12 months
₹379.65 month-end · +73.4% since Feb '25
52-week range ₹225.05 to ₹471.80 · 1-year volatility 52.0%
How rough has the ride been?
Drawdown from peak
Largest drawdowns
-51.7% (2025-10 peak to 2026-03 low, not yet recovered)
-17.0% (2025-03 peak to 2025-04 low, recovered 2025-04)
-16.5% (2025-04 peak to 2025-05 low, recovered 2025-05)
Most recent volume spikes
2026-09-23: 6.2x the 50-day median, price -0.2% that day
2026-09-18: 6.4x the 50-day median, price +1.7% that day
2026-09-15: 9x the 50-day median, price +1.8% that day
Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- P/E ↓14th
- 12M momentum30th
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What is the price implying?
At a P/E of 88.7x, the price would imply about 33.8%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.
Fewer than six years of annual earnings are available, which is too little to measure delivered growth.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What prices imply across Health Technology The market-wide Expectations lists
Key figures
- Share Priceclose 9 Nov
- ₹379.65
- P/E
- 88.7x
- Market Cap
- ₹4944 cr
- Revenue (TTM)
- ₹166 cr
- P/S
- 29.8x
- Promoter Holding
- 70.9%
- 12M Momentum
- -6.9%
52-week range
Price risk
Balance sheet & cash
Are profits backed by cash?
Other income reliance3%Within range
Other income as a share of pre-tax profit (trailing twelve months): 3.2%. Bands: below 15%, 15% to 35%, above 35%.
Tax rate—Not enough data
Not enough reported data to compute this.
Cash conversion—Not enough data
Not enough reported data to compute this.
Free cash flow—Not enough data
Not enough reported data to compute this.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress—Not enough data
Not enough reported data to compute this.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
Who has been buying and selling?
- Over 2 years, institutional and promoter holdings were broadly unchanged.
- The number of shareholders fell from 31,271 to 27,010 (-14%) between Sep 2024 and Jun 2026.
Holdings, Jun '26
How each group changed
Number of shareholders
Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.
What happened next to similar setups
- We found 50 past situations where a non-financial company looked like GUJARAT THEMIS BIOSYN LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
- Over the following 12 months the middle half of them returned −38% to +23% vs the market, against −4% for all non-financial companies in the same months.
- The gap against the base rate (−3.8%, 80% range −23.6% to +7.8%) is within what chance and overlapping periods produce.
Where the 50 outcomes landed
Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge
50 past situations · 50 companies · 32 months · 2020–2025
The closest matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| VIJAYA Health Services |
May 2025 | 74x | 19% | +18% | −23% | +37% |
| NELCO Electronic Technology |
Jul 2020 | 35x | 20% | −4% | −26% | +16% |
| BIGBLOC Non-Energy Minerals |
May 2024 | 101x | 33% | +44% | −16% | −45% |
| NEOGEN Process Industries |
Oct 2021 | 88x | 17% | +92% | −13% | +21% |
| CARYSIL Consumer Durables |
May 2022 | 59x | 20% | +6% | −34% | −13% |
Show the other 3 matches
How reliable is this?
Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, P/E and revenue growth. One match per company and at most 7 from any one month.
Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.
What changed?
7 events since Apr '25
- SepPriceVolume reached 25.4x its 50-day median on 2026-09-08; price +5.6% that day.
- AprPriceVolume reached 159.7x its 50-day median on 2026-04-24; price +10.9% that day.
- MarPriceFell 52% from the Oct 2025 peak to the Mar 2026 low.
- FebPriceVolume reached 7.1x its 50-day median on 2026-02-18; price +6.8% that day.
- DecPriceVolume reached 17.7x its 50-day median on 2025-12-24; price +7.3% that day.
- SepPriceVolume reached 15.1x its 50-day median on 2025-09-22; price +6.4% that day.
- AprPriceVolume reached 13.8x its 50-day median on 2025-04-17; price +8.9% that day.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history22 months · 2025-02 to 2026-11
| Month | P/E | Revenue (TTM) |
|---|---|---|
| 2026-11 | 88.7x | ₹166 cr |
| 2026-10 | 84.9x | ₹166 cr |
| 2026-09 | 90.6x | ₹166 cr |
| 2026-08 | 98.6x | ₹166 cr |
| 2026-07 | 83.7x | ₹166 cr |
| 2026-06 | 92.9x | ₹166 cr |
| 2026-05 | — | — |
| 2026-04 | — | — |
| 2026-03 | — | — |
| 2026-02 | — | — |
| 2026-01 | — | — |
| 2025-12 | — | — |
| 2025-11 | — | — |
| 2025-10 | — | — |
| 2025-09 | — | — |
| 2025-08 | — | — |
| 2025-07 | — | — |
| 2025-06 | — | — |
| 2025-05 | — | — |
| 2025-04 | — | — |
| 2025-03 | — | — |
| 2025-02 | — | — |